Hope E Uronis

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Anal cancer: an overview
    Hope E Uronis
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 12:524-34. 2007
  2. pmc Palliative management of refractory dyspnea in COPD
    Hope E Uronis
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Chron Obstruct Pulmon Dis 1:289-304. 2006
  3. doi request reprint Oxygen for relief of dyspnea: what is the evidence?
    Hope E Uronis
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Support Palliat Care 2:89-94. 2008
  4. pmc A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
    Hope E Uronis
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:271-2. 2013
  5. pmc Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
    John H Strickler
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:251-8. 2012
  6. pmc A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
    Hope E Uronis
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Med 2:316-24. 2013
  7. pmc A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
    Ivy Altomare
    Duke University Medical Center, Durham, North Carolina, USA
    Oncologist 16:1131-7. 2011
  8. doi request reprint Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus
    Yingmiao Liu
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
    Mol Cancer Ther 14:1048-56. 2015
  9. doi request reprint A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors
    Hope E Uronis
    Duke Cancer Institute, Duke University Medical Center, Box 3052, Durham, NC, USA
    Cancer Chemother Pharmacol 75:343-52. 2015
  10. pmc A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
    Gordana Vlahovic
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:95-102. 2012

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Anal cancer: an overview
    Hope E Uronis
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 12:524-34. 2007
    ..We present a case of anal cancer followed by a general discussion of both risk factors and treatment...
  2. pmc Palliative management of refractory dyspnea in COPD
    Hope E Uronis
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Chron Obstruct Pulmon Dis 1:289-304. 2006
    ..Topics include oxygen, opioids, psychotropic drugs, inhaled furosemide, Heliox, rehabilitation, nutrition, psychosocial support, breathing techniques, and breathlessness clinics...
  3. doi request reprint Oxygen for relief of dyspnea: what is the evidence?
    Hope E Uronis
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Support Palliat Care 2:89-94. 2008
    ..e., when PaO2 is >/=55 mmHg; also known as palliative oxygen)...
  4. pmc A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas
    Hope E Uronis
    Duke Cancer Institute, Durham, North Carolina 27710, USA
    Oncologist 18:271-2. 2013
    ..We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas...
  5. pmc Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
    John H Strickler
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:251-8. 2012
    ..To define the maximum tolerated dose, clinical toxicities, and pharmacodynamics of bevacizumab, everolimus, and panobinostat (LBH-589) when administered in combination to patients with advanced solid tumor malignancies...
  6. pmc A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
    Hope E Uronis
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Med 2:316-24. 2013
    ..Data suggest that continued evaluation of combination antiangiogenesis therapies may be clinically useful. ..
  7. pmc A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
    Ivy Altomare
    Duke University Medical Center, Durham, North Carolina, USA
    Oncologist 16:1131-7. 2011
    ..A phase I study of bevacizumab plus everolimus demonstrated that the combination is safe; activity was seen in several patients with refractory mCRC...
  8. doi request reprint Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus
    Yingmiao Liu
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina
    Mol Cancer Ther 14:1048-56. 2015
    ..Several markers correlated with both PFS and OS. Interestingly, these markers are known to be associated with inflammation and IGF signaling, key modulators of mTOR biology. Mol Cancer Ther; 14(4); 1048-56. ©2015 AACR. ..
  9. doi request reprint A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors
    Hope E Uronis
    Duke Cancer Institute, Duke University Medical Center, Box 3052, Durham, NC, USA
    Cancer Chemother Pharmacol 75:343-52. 2015
    ..We also explored the effects of these agents on plasma-based biomarkers and wound angiogenesis...
  10. pmc A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors
    Gordana Vlahovic
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 70:95-102. 2012
    ..This study evaluated the maximum tolerated dose/recommended phase II dose and safety and tolerability of bevacizumab, everolimus and panitumumab drug combination...
  11. doi request reprint Management of dyspnea in patients with chronic obstructive pulmonary disease
    Amy P Abernethy
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center DUMC, Durham, North Carolina 27710, USA
    Wien Med Wochenschr 159:583-90. 2009
    ..Topics include oxygen, opioids, psychotropic drugs, inhaled frusemide, Heliox28, nutrition, psychosocial support, and breathing techniques...
  12. doi request reprint Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer
    Hope E Uronis
    Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Pain Symptom Manage 44:741-9. 2012
    ..Existing dyspnea measures fail to adequately address its multidimensionality. A Japanese group developed and validated the Cancer Dyspnea Scale (CDS) for assessing dyspnea in patients with advanced lung cancer...
  13. pmc Preoperative chemoradiotherapy for locally advanced gastric cancer
    Joseph M Pepek
    Department of Radiation Oncology, Duke University School of Medicine, Box 3085, Durham, NC 27710, USA
    Radiat Oncol 8:6. 2013
    ..To examine toxicity and outcomes for patients treated with preoperative chemoradiotherapy (CRT) for gastric cancer...
  14. pmc The role of local excision in invasive adenocarcinoma of the ampulla of Vater
    Jim Zhong
    Duke University School of Medicine, Duke University Medical Center, USA
    J Gastrointest Oncol 4:8-13. 2013
    ..Given the mortality associated with pancreaticoduodenectomy, some patients may benefit from local resection. A single-institution outcomes analysis was performed to define the role of local resection...
  15. doi request reprint Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis
    Hope E Uronis
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA
    Thorax 70:492-4. 2015
    ..Continuous exertional oxygen can relieve dyspnoea in mildly or non-hypoxemic COPD, but evidence from larger clinical trials is needed. ..
  16. pmc Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
    Fatima Rangwala
    Duke University Medical Center, Seeley G Mudd Bldg 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA
    Invest New Drugs 32:700-9. 2014
    ..To define maximum tolerated dose (MTD), toxicities, and pharmacodynamics of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumor patients...
  17. pmc Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
    John H Strickler
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA
    Invest New Drugs 32:330-9. 2014
    ..We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC)...
  18. pmc Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma
    A Paiman Ghafoori
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Radiat Oncol Biol Phys 81:654-9. 2011
    ..Extrahepatic cholangiocarcinoma is an uncommon but lethal malignancy. We analyzed the role of definitive chemoradiotherapy for patients with nonmetastatic, locally advanced extrahepatic cholangiocarcinoma treated at a single institution...
  19. pmc A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
    Karen E Bullock
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 67:465-74. 2011
    ..This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus, and erlotinib combination...